MGO One Seven’s Bristol-Myers Squibb BMY Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.32M | Sell |
40,184
-4,241
| -10% | -$244K | 0.04% | 449 |
|
|
2026
Q1 | $2.69M | Buy |
44,425
+1,610
| +4% | +$93.9K | 0.05% | 368 |
|
|
2025
Q4 | $2.31M | Buy |
42,815
+9,168
| +27% | +$441K | 0.05% | 398 |
|
|
2025
Q3 | $1.52M | Buy |
33,647
+11,042
| +49% | +$516K | 0.04% | 471 |
|
|
2025
Q2 | $1.05M | Sell |
22,605
-2,328
| -9% | -$114K | 0.03% | 500 |
|
|
2025
Q1 | $1.52M | Sell |
24,933
-4,443
| -15% | -$259K | 0.06% | 336 |
|
|
2024
Q4 | $1.66M | Buy |
29,376
+5,202
| +22% | +$291K | 0.06% | 312 |
|
|
2024
Q3 | $1.25M | Sell |
24,174
-253
| -1% | -$11.9K | 0.05% | 351 |
|
|
2024
Q2 | $1.01M | Buy |
24,427
+1,632
| +7% | +$73K | 0.05% | 377 |
|
|
2024
Q1 | $1.24M | Buy |
22,795
+983
| +5% | +$50.1K | 0.06% | 296 |
|
|
2023
Q4 | $1.12M | Sell |
21,812
-1,769
| -8% | -$92.9K | 0.06% | 299 |
|
|
2023
Q3 | $1.37M | Sell |
23,581
-239
| -1% | -$14.6K | 0.11% | 216 |
|
|
2023
Q2 | $1.52M | Sell |
23,820
-16,666
| -41% | -$1.12M | 0.14% | 186 |
|
|
2023
Q1 | $2.81M | Buy |
40,486
+15,250
| +60% | +$1.08M | 0.18% | 143 |
|
|
2022
Q4 | $1.82M | Sell |
25,236
-704
| -3% | -$53.1K | 0.18% | 134 |
|
|
2022
Q3 | $1.89M | Buy |
25,940
+2,609
| +11% | +$189K | 0.07% | 155 |
|
|
2022
Q2 | $1.8M | Sell |
23,331
-7,740
| -25% | -$589K | 0.25% | 97 |
|
|
2022
Q1 | $2.27M | Buy |
31,071
+2,331
| +8% | +$157K | 0.24% | 109 |
|
|
2021
Q4 | $1.79M | Buy |
28,740
+12,071
| +72% | +$708K | 0.19% | 141 |
|
|
2021
Q3 | $974K | Sell |
16,669
-1,242
| -7% | -$81.8K | 0.12% | 205 |
|
|
2021
Q2 | $1.2M | Buy |
17,911
+1,959
| +12% | +$128K | 0.17% | 156 |
|
|
2021
Q1 | $1.01M | Buy |
15,952
+1,393
| +10% | +$86.7K | 0.17% | 150 |
|
|
2020
Q4 | $903K | Buy |
14,559
+460
| +3% | +$28.3K | 0.19% | 137 |
|
|
2020
Q3 | $850K | Sell |
14,099
-920
| -6% | -$55.4K | 0.2% | 127 |
|
|
2020
Q2 | $883K | Buy |
15,019
+3,060
| +26% | +$183K | 0.23% | 109 |
|
|
2020
Q1 | $666K | Buy |
11,959
+2,547
| +27% | +$156K | 0.23% | 119 |
|
|
2019
Q4 | $604K | Buy |
+9,412
| New | +$539K | 0.16% | 181 |
|
|
2019
Q1 | – | Sell |
-2,591
| Closed | -$134K | – | 556 |
|
|
2018
Q4 | $134K | Buy |
+2,591
| New | +$139K | 0.06% | 371 |
|
|
2018
Q1 | $115K | Sell |
1,811
-2
| -0.1% | -$129 | 0.05% | 397 |
|
|
2017
Q4 | $111K | Buy |
+1,813
| New | +$113K | 0.05% | 409 |
|
Other funds holding BMY
MGO One Seven's BMY Position: Q2 2026 in Review
MGO One Seven reduced its Bristol-Myers Squibb (BMY) stake by 9.5% in Q2 2026, selling an estimated $244K and leaving 40,184 shares worth $2.32M. The position accounts for 0.04% of the portfolio, ranked #449.
MGO One Seven first reported a position in BMY in Q4 2017 and has held it in 30 quarters since. The position peaked at $2.81M in Q1 2023. 2,508 funds tracked by Wall St. Rank hold BMY as of Q2 2026.
- MGO One Seven held 40,184 shares of Bristol-Myers Squibb worth $2.32M as of Q2 2026.
- MGO One Seven sold 4,241 Bristol-Myers Squibb shares in Q2 2026, an estimated $244K.
- Bristol-Myers Squibb made up 0.04% of MGO One Seven's portfolio in Q2 2026, its #449 holding.
- MGO One Seven first reported a position in Bristol-Myers Squibb in Q4 2017 and has held it in 30 quarters since.
- MGO One Seven's Bristol-Myers Squibb position peaked at $2.81M in Q1 2023.
- 2,508 funds tracked by Wall St. Rank held Bristol-Myers Squibb as of Q2 2026.
Based on MGO One Seven's 13F filing for Q2 2026, filed 31 Jul 2026.